NCT02027961, a Phase I, open‐label, dose‐escalation and dose‐expansion study, tested the safety, tolerability, and preliminary efficacy of durvalumab (PD‐L1 inhibitor) combined with dabrafenib ± trametinib for advanced melanoma. The gene discussed is CD274; the disease is melanoma.